Zocere

Zocere is a biotechnology company focused on developing novel neuroprotective drugs to treat brain injuries resulting from stroke and trauma. The company's lead candidate, ZC-001, is a peptide-based therapeutic designed to inhibit the Striatal-Enriched Protein Tyrosine Phosphatase (STEP), an enzyme that plays a critical role in the neuronal cell death process following an ischemic event. By targeting STEP, Zocere aims to extend the treatment window for stroke patients and minimize permanent brain damage. The technology was originally developed at the University of New Mexico and is being advanced toward clinical trials to address significant unmet needs in neurology.